Alnylam's 29% Face-Plant Is Old News. The Question Is Whether Management Can Stop Doing That

# Alnylam's 29% Face-Plant Is Old News. The Question Is Whether Management Can Stop Doing That

Six weeks ago, Alnylam took a body blow that would've ended lesser stocks: a 29% intraday drubbing on July 30 after management cut full-year TTR guidance from $4.4–$4.7 billion down to $4.2–$4.5 billion. Since then it's clawed most of that back on the strength of some genuinely good science. Right now the stock is sitting around $250-$260, caught in a tug-of-war between "best-in-class RNAi franchise with elite margins" and "company that just told you its flagship drug isn't selling as fast as promised." Both of those things are true at the same time, and that's exactly why this name is interesting right now instead of just being another biotech chart with a crater in it.

Let's start with the crater. Q2 revenue actually grew 74% year-over-year to roughly $1.2 billion, and the TTR franchise (Amvuttra plus Onpattro) cracked $1 billion in a single quarter for the first time ever. That's not a company falling apart — that's a company whose growth rate simply wasn't growing fast enough to justify the multiple the Street had built in. Softer-than-expected Amvuttra demand forced the guidance trim, and Cantor Fitzgerald's Olivia Brayer Saunders called it a "one-two punch," pairing the cut with an earlier July disappointment in the eplontersen study. Markets don't forgive nuance in moments like that — they just sell.

Then came the redemption arc. At ESC Congress in late August/early September, HELIOS-B data reinforced that Amvuttra and patisiran deliver real benefit in ATTR-CM and hATTR-PN — critically, even in patients already stabilized on BridgeBio's tafamidis. That's not a footnote. It directly answers the question the eplontersen setback raised: does TTR silencing still matter for patients already on other therapy? The ESC crowd's read was "market expansion, not contraction," and a subsequent ~3.6% pop got chalked up to "company-specific momentum and sector positioning" rather than any single headline — which is quant-speak for "the market is starting to believe again, catalyst by catalyst."

Here's my actual take: this is a stock where the fundamentals and the sentiment are running on different clocks. The fundamentals — 74% revenue growth, a $1B+ quarterly TTR franchise, the "Alnylam 2030" plan targeting a 25% revenue CAGR and $1.8 billion in operating profit — are genuinely elite for a company this size. A forward P/E near 20 with a PEG under 0.4 is not the profile of an overheated growth stock; it's the profile of a company the market is actively distrusting despite the numbers. That distrust is earned. Management set an ambitious 2026 bar, missed it, and openly admitted as much on the call. Sentiment doesn't repair on good vibes from a European cardiology conference — it repairs when the next print confirms the reset was conservative rather than the start of a slide.

That's why October 29's Q3 earnings is the whole ballgame, not ESC. If Amvuttra scaling shows real sequential acceleration and management holds or reaffirms the trimmed $4.2–$4.5B range, this stock has every reason to test $270-$290 resistance and put the "credibility problem" narrative to bed. If there's even a whiff of a second guidance cut, $210-$220 is not a hypothetical — it's where the crowd goes to reprice execution risk all over again, and this time there won't be an ESC congress conveniently scheduled to bail out sentiment.

I'd also flag that a couple of dates floating around trader calendars — a September 20 "Phase 3 TTR trials announcement" and a November 10 "Phase 3 trial results release" — don't have direct confirmation in company sourcing. Treat those as rumor-tier until Alnylam's IR page says otherwise; don't trade a binary event that might not exist.

Bottom line: Alnylam is a fundamentally strong company that just proved it can still disappoint the market on execution, then partially talk its way back with science. That's a HOLD, not a conviction buy and not a flight risk — a $240-$275 range name waiting on one earnings call to decide which story is actually true. The TTR franchise is real. The question is whether management's forecasting is.